Scientific Clinical Wide Aspect Ratio 1200 384

Scientific & Clinical Advisors

Trusted advisors with deep expertise

We are able to turn to our advisors to discuss new ideas and approaches to our science and clinical advancements.

  • Siddhartha Mukherjee 1x1

    Siddhartha Mukherjee, MD, DPhil

    Chair of the Scientific Advisory Board

    Siddhartha Mukherjee, MD, DPhil is an Associate Professor of Medicine at Columbia University and a Staff Physician at Columbia University Medical Center. He is the author of “The Emperor of All Maladies: A Biography of Cancer,” winner of the 2011 Pulitzer Prize in general nonfiction, “...

  • Hans Peter Kim 1x1

    Hans-Peter Kiem, MD, PhD

    Scientific & Clinical Advisor

    The research of Hans-Peter Kiem, MD, PhD has focused on stem cell and transplantation biology, cell and gene therapy, and the development and use of novel gene-editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and ...

  • Dan Littman 1x1

    Dan Littman, MD, PhD

    Scientific Advisor

    Dan Littman, MD, PhD is a Howard Hughes Medical Institute Investigator and the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology at the New York University (NYU) School of Medicine. Dan has made numerous groundbreaking discoveries ...

Chair of the Scientific Advisory Board

Siddhartha Mukherjee, MD, DPhil

Siddhartha Mukherjee, MD, DPhil is an Associate Professor of Medicine at Columbia University and a Staff Physician at Columbia University Medical Center. He is the author of “The Emperor of All Maladies: A Biography of Cancer,” winner of the 2011 Pulitzer Prize in general nonfiction, “The Laws of Medicine,” and “The Gene: An Intimate History.” Siddhartha’s laboratory seeks to understand the biology of blood development, with a special interest in malignant and premalignant blood diseases, and a goal of developing novel therapeutic strategies. Siddhartha trained as a hematologist and oncologist at the Dana-Farber Cancer Institute of Harvard Medical School and was on the staff at the Massachusetts General Hospital. He obtained a DPhil in immunology from Oxford as a Rhodes Scholar and an MD from Harvard Medical School.

Siddhartha Mukherjee 5x7

Scientific & Clinical Advisor

Hans-Peter Kiem, MD, PhD

The research of Hans-Peter Kiem, MD, PhD has focused on stem cell and transplantation biology, cell and gene therapy, and the development and use of novel gene-editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer, in particular, hematologic malignancies. He is a clinically active hematologist/oncologist seeing patients on the marrow transplant, immunotherapy, and MDS/AML service. Hans-Peter has extensive experience training students and postdoctoral fellows and has mentored more than 50 trainees in his lab over the past 20 years. Many of his trainees now hold tenured faculty positions in the U.S. and Germany. Hans-Peter has been the Sponsor of four clinical gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and he is the PI or Co-PI of many R01 or Program Project grants. Hans-Peter has also served on the NIH Recombinant DNA Advisory Committee (RAC) for five years, the last year as Chair, and served as the Chair of the Stem Cell Committees for both the American Society for Gene and Cell Therapy (ASGCT) and the American Society of Hematology.

Hans-Peter received his MD and PhD degrees from the University of Ulm in Germany and then joined Dr. Karl Blume’s research group at Stanford University as a research fellow, working with Drs. Sklar and Cleary to study molecular abnormalities and minimal residual in patients with lymphoma (Oncogene 1990; Blood 1991) and with Drs. Weissman and Negrin on the use of a novel immunodeficient mouse model for lymphoma (J. Exp. Med. 1991). After a two-year fellowship at Stanford, Hans-Peter went on to complete his residency in Internal Medicine and his Physician/Scientist training at Vanderbilt University. He joined the Fred Hutchinson Cancer Research Center in 1992, where he completed his clinical fellowship in Oncology.

Hans Peter Kim 1x1

Scientific Advisor

Dan Littman, MD, PhD

Dan Littman, MD, PhD is a Howard Hughes Medical Institute Investigator and the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology at the New York University (NYU) School of Medicine. Dan has made numerous groundbreaking discoveries in the field of virology and immunology, including identification and isolation of receptors required for human immunodeficiency virus (HIV) entry, molecular mechanisms of immune cells that mediate autoimmunity and the role of specific members of the gut microbiota in T-cell differentiation. Dan is a Fellow of the American Academy of Arts and Sciences and is a Member of the National Academy of Sciences. He was awarded the 2004 New York City Mayor’s Award for Excellence in Science and Technology and the 2016 Vilcek Prize in Biomedical Science.

Dan Littman 1x1
The Science

The science behind our approach

Vor Bio is working to potentially protect HSCs from targeted therapies post-transplant.

Our founding story

Vor Bio was founded on an elegant and profound idea from Dr. Siddhartha Mukherjee—protect the healthy cells, expose the cancer.